QSAR Study on 5-Lipoxygenase Activating Protein (FLAP) Inhibitors: The Derivatives of 2,2-Bisaryl-Bicycloheptane

被引:0
|
作者
Sharma, Brij Kishore [1 ]
Pilania, Pradeep [1 ]
Singh, Prithvi [1 ]
机构
[1] SK Govt Coll, Dept Chem, Sikar 332001, India
关键词
2,2-bisaryl-bicycloheptane derivatives; 5-lipoxygenase activating protein (FLAP) inhibitors; Combinatorial protocol in multiple linear regression (CP-MLR); Partial least square (PLS) analysis; LEUKOTRIENE BIOSYNTHESIS INHIBITORS; VARIABLE SELECTION; SUBSTITUTED 2,2-BISARYL-BICYCLOHEPTANES; POTENT; INDOLES; DISEASE; MODELS; ACID;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The FLAP inhibitory activity of 2,2-bisaryl-bicycloheptane derivatives has been quantitatively analyzed in terms of Dragon descriptors. The derived QSAR models have provided rationales to explain the FLAP inhibitory activity of 2,2-bisaryl-bicycloheptane derivatives. The presence of quinolinylmethoxy substituent at R(2)-position in a molecular structure is a crucial feature for the FLAP inhibitory activity. The occurrence of R-CR-X type structural fragment (descriptor C-028) and higher number of sulfur atoms (descriptor nS) in a molecular structure are prevalent to rationalize the FLAP actions of bicycloheptane derivatives. The topological charge indices (descriptors GGI3, 3(rd) order Galvez topological charge index; and JGI4, 4(th) order Galvez mean topological charge index), path/walk ratio 2 (Randic's molecular shape descriptor PW2) and atomic polarizabilities at lag 2 (descriptor GATS2p, Geary autocorrelation of lag 2 weighted by atomic polarizabilities) are also important to explain the FLAP activity. The PLS analysis has also confirmed the dominance of information content of CP-MLR identified descriptors. Applicability domain analysis revealed that the suggested model matches the high quality parameters with good fitting power and the capability of assessing external data, and all of the compounds were within the applicability domain of the proposed models and were evaluated correctly.
引用
收藏
页码:32 / 43
页数:12
相关论文
共 50 条
  • [1] Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein
    Macdonald, Dwight
    Brideau, Christine
    Chan, Chi Chung
    Falgueyret, Jean-Pierre
    Frenette, Richard
    Guay, Jocelyne
    Hutchinson, John H.
    Perrier, Helene
    Prasit, Peptiboon
    Riendeau, Denis
    Tagari, Philip
    Therien, Michel
    Young, Robert N.
    Girard, Yves
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (06) : 2023 - 2027
  • [2] DISCOVERY OF INHIBITORS OF THE 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP)
    YOUNG, RN
    GILLARD, JW
    HUTCHINSON, JH
    LEGER, S
    PRASIT, P
    JOURNAL OF LIPID MEDIATORS, 1993, 6 (1-3): : 233 - 238
  • [3] Molecular docking and 3-D QSAR studies of substituted 2,2-bisaryl-bicycloheptanes as human 5-Lipoxygenase-Activating Protein (FLAP) inhibitors
    Ma, Xiang
    Zhou, Lu
    Zuo, Zhi-Li
    Liu, Jian
    Yang, Min
    Wang, Rong-Wei
    QSAR & COMBINATORIAL SCIENCE, 2008, 27 (09): : 1083 - 1091
  • [4] QSAR modeling of benzoquinone derivatives as 5-lipoxygenase inhibitors
    T.K.Shameera Ahamed
    Vijisha K.Rajan
    K.Muraleedharan
    Food Science and Human Wellness, 2019, 8 (01) : 53 - 62
  • [5] QSAR modeling of benzoquinone derivatives as 5-lipoxygenase inhibitors
    Ahamed, T. K. Shameera
    Rajan, Vijisha K.
    Muraleedharan, K.
    FOOD SCIENCE AND HUMAN WELLNESS, 2019, 8 (01) : 53 - 62
  • [6] Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors
    Frenette, R
    Hutchinson, JH
    Léger, S
    Thérien, M
    Brideau, C
    Chan, CC
    Charleson, S
    Ethier, D
    Guay, J
    Jones, TR
    McAuliffe, M
    Piechuta, H
    Riendeau, D
    Tagari, P
    Girard, Y
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (16) : 2391 - 2396
  • [7] The effect of 5-lipoxygenase-activating protein (FLAP) on substrate utilization by 5-lipoxygenase
    Vickers, PJ
    Deluca, C
    Wong, E
    Abramovitz, M
    EICOSANOIDS AND OTHER BIOACTIVE LIPIDS IN CANCER, INFLAMMATION, AND RADIATION INJURY 2, PTS A AND B, 1997, 400 : 145 - 151
  • [8] 5-lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension
    Wright, L
    Tuder, RM
    Wang, J
    Cool, CD
    Lepley, RA
    Voelkel, NF
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (01) : 219 - 229
  • [9] Inhibitors of 5-lipoxygenase activating protein: WO 2008/030369
    Tavridou, Anna
    Manolopoulos, Vangelis G.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (10) : 1473 - 1476
  • [10] Characterization of the interaction of human 5-lipoxygenase with its activating protein FLAP
    Haefner, Ann-Kathrin
    Gerstmeier, Jana
    Hoernig, Michael
    George, Sven
    Ball, Ann-Katrin
    Schroeder, Mirjam
    Garscha, Ulrike
    Werz, Oliver
    Steinhilber, Dieter
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2015, 1851 (11): : 1465 - 1472